(Q43759271)

26 November 2017

title

Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals (English)

1 reference

26 November 2017

1 reference

Touloumi G

1

1 reference

26 November 2017

Paparizos V

2

1 reference

26 November 2017

Sambatakou H

3

1 reference

26 November 2017

Katsarou O

4

1 reference

26 November 2017

Chrysos G

5

1 reference

26 November 2017

Kordossis T

6

1 reference

26 November 2017

Antoniadou A

7

1 reference

26 November 2017

Hatzitheodorou H

8

1 reference

26 November 2017

Stavrianeas N

9

1 reference

26 November 2017

Gargalianos P

10

1 reference

26 November 2017

Karafoulidou A

11

1 reference

26 November 2017

Lazanas M

12

1 reference

26 November 2017

Giamarelou H

13

1 reference

26 November 2017

Hatzakis A

14

1 reference

26 November 2017

publication date

1 January 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

2

1 reference

26 November 2017

issue

1

1 reference

26 November 2017

page(s)

6-16

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Virological response to protease inhibitor therapy in an HIV clinic cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

HIV treatment failure: testing for HIV resistance in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYN11-XJ4L-9YHF-19E4

10.1310/YN11-XJ4L-9YHF-19E4

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference